

Preparation and Evaluation of Matrix Containing Lidocaine and Prilocaine for Using in Transdermal Films

Abstract

Background: Lidocaine and prilocaine are amide-type local anesthetic agents that are expectedly adequate to create a rapid pharmacological effect immediately after using transdermal delivery system. **Objective:** The aim of this study was to investigate the effect of hydrophilic and hydrophobic materials on drug release from different polymeric films containing lidocaine and prilocaine. **Materials and Methods:** Several films containing lidocaine and prilocaine were prepared using ethyl cellulose (EC) or hydroxypropyl methylcellulose (HPMC) polymers. The effect of propylene glycol (PG) and polyethylene glycol 4000 (as permeation enhancers) and triacetin or dibutyl phthalate (DBP) as plasticizer on tensile strength, moisture absorption, content uniformity, and drug release properties were investigated. *In vitro* permeations studies were carried out using Franz diffusion cells and samples were analyzed by high-performance liquid chromatography for each drug. **Results:** DBP unlike triacetin had a dramatic effect on drug release rate and moisture absorption in HPMC films. The presence of PG on the formulations containing EC caused an increase in the moisture absorption and drug release and shifted the mechanism of release from Fickian diffusion to Case-II transport. PEG4000 was not a significant effect on these variables in the HPMC films. **Conclusion:** Hydrophilic additives like PG when used in an water-insoluble membrane act as a channeling agent and increase the rate of drug release because in dissolution medium they dissolve out of the film and leave channels from which drug can be released more rapidly.

Keywords: Ethyl cellulose transdermal film, hydroxypropyl methylcellulose, lidocaine, prilocaine

Introduction

Transdermal drug delivery (TDD) offers a noninvasive approach to avoid the first-pass effect and can sustain plasma levels within the therapeutic window for extended periods^[1]. TDS formulations are usually ointments, cream semisolid emulsions, or films.^[2] Transdermal films are usually well accepted due to their ease of applying, advantages in keeping with the treatment schedule, and less interference with daily life. They represent a valuable alternative when oral administration is difficult. For example, when a patient is unable to swallow or may result in erratic absorption due to nausea and vomiting. Moreover, they are noninvasive drug delivery systems intended for application on skin to achieve systemic effects.^[1,3-6] Unlike semisolids, patch does not need occlusive dressing. The choice of the most appropriate polymeric composition is essential for patch characteristics in terms of mechanical properties and drug release kinetics.^[2] Lidocaine and prilocaine are amide-type local anesthetic agents that are

expected to be adequate to create a rapid pharmacological effect immediately after topical administration.^[7,8] Plasma protein binding lidocaine and prilocaine are about 66%–70% and 55%, respectively.^[9,10] After oral administration, lidocaine undergoes extensive first-pass hepatic metabolism with a bioavailability of about 35% and has short half-life (1–2 h).^[9,10] Moreover, half-life of prilocaine is short (0.76–1.35 h).^[11] Eutectic mixture of lidocaine and prilocaine in a weight ratio of 1:1 has a melting point below the room temperature and in the mixture, two local anesthetics change from crystal to liquid form. EMLA cream (Eutectic Mixture of Local Anesthetics) is a 5% emulsion that contains eutectic mixture of lidocaine and prilocaine (2.5% each of them).^[1] This eutectic mixture increases systemic absorption of the two anesthetics in comparison to applying them separately. This system is used for preparation of EMLA anesthetic single disk too. The disk contains an absorbent cellulose disk containing 1-g EMLA emulsion. The depth and duration time of dermal anesthetic effect of EMLA on intact skin depends on the time spent for topical administration. To

Maryam Kouchak^{1,2},
Saeed Rezaee³,
Nasrin Moshabeh¹,
Somayeh Handali⁴

¹Nanotechnology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, ²Department of Pharmaceutics, Faculty of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran, ³Department of Pharmaceutics, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran, ⁴Medical Biomaterial Research Centre (MBRC), Tehran University of Medical Sciences, Tehran, Iran

Address for correspondence:
Dr. Somayeh Handali,
Medical Biomaterial Research
Centre (MBRC), Tehran
University of Medical Sciences,
Tehran, Iran.
E-mail: handali_s81@yahoo.com

Access this article online

Website:
www.jrpsjournal.com

DOI:10.4103/jrptps.JRPTPS_71_18

Quick Response Code:



How to cite this article: Kouchak M, Rezaee S, Moshabeh N, Handali S. Preparation and evaluation of matrix containing lidocaine and prilocaine for using in transdermal films. *J Rep Pharm Sci* 2019;8:270-6.

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

obtain an adequate anesthesia for clinical procedures such as intravenous catheter insertion and intravenous cannulation, EMLA disk as a cover bandage should be applied for at least an hour and should be used in the split skin graft for at least 2 h. Satisfactory anesthesia is achieved 1 h after the application and reaches maximum effect at 2–3 h.^[12]

The aim of this study was to provide a polymer matrix containing a eutectic mixture of lidocaine and prilocaine in order to apply in the skin films and study its mechanical properties and profile release of drug from them.

Materials and Methods

Hydroxypropyl methylcellulose (HPMC, 50 cPs), ethyl cellulose (EC, 100 cPs), polyethylene glycol 4000 (PEG 4000), DBP, and triacetin were purchased from Merck (Germany). Lidocaine and prilocaine were obtained from Shahid Rezakhani Co. (Tehran, Iran) and Orgamol (Evionnaz, Switzerland), respectively. Propylene glycol (PG) was purchased from Sepidaj Co. (Tehran, Iran). All other materials used in this study were of analytical reagent grade.

Preparation of Hydroxypropyl Methylcellulose Matrixes

The films were prepared using casting/solvent evaporation method. HPMC was dispersed in hot distilled water under stirring to form a homogeneous mixture. The prepared gel was placed in refrigerator to remove air bubbles. Polymer solution, PG, and DBP or triacetin as plasticizers were mixed. Lidocaine, prilocaine, and PEG 4000 were dissolved in ethanol (96% v/v) and added to the mixture. The prepared solution was poured in a Petri dish and allowed to dry at 40–45°C for 24 h. The compositions of different formulations are shown in Table 1.

Preparation of Ethyl Cellulose Matrixes

Drugs, EC, PG, and triacetin were dissolved in a mixture of methanol and dichloromethane (1:1 v/v). The films were prepared using casting and solvent evaporation as mentioned

above. Compositions of different formulations of films are shown in Table 2.

Characterization of the Films

Physical appearance

Each formulation was visually inspected for film formation capability, ease of separation from the mold, transparency, and presence of bubble.

Moisture absorption

The films were kept in an oven at 50°C to reach a constant weight. The pieces of each film (3.14 cm²) were cut, weighed accurately, and held in a desiccator containing saturated potassium bromide (84% RH) for a week. The samples were taken out and reweighed. The moisture absorption was calculated as the difference between final and initial weight with respect to initial surface area.

Tensile strength

The tensile strength properties of the films were evaluated using a texture analyzer (WDW, Japan). The specimens (3 × 5 cm²) were positioned between two mounting clamps and were pulled by the top clamp at a rate of 50 cm/h. The tensile strength at break was calculated.^[13,14]

Drug content analysis

To determine content uniformity of HPMC films, samples (1 cm × 1 cm) were precisely cut from three random sites in each film and placed into dialysis bag and hang in 20-mL distilled water for 24 h. The bag was removed and the concentration of drugs was measured by high-performance liquid chromatography (HPLC) (Waters, USA). To determine content uniformity of EC films, samples were immersed in 4 mL of methanol and the volume was made up to 100 mL with distilled water. The solution was filtered and the drug content was measured by HPLC.

Chromatographic separation was performed using a C18 column (25 cm, 4.6 mm) maintained at 25°C, using mobile phase phosphate buffer (pH 8) and methanol (70:30 v/v) and

Table 1: Compositions of different formulations of films prepared using HPMC

Formulation	HPMC 10% (g)	PEG (g)	Triacetin (g)	DBP (g)	PG (g)	Ethanol96% v/v (mL)	Lidocaine (g)	Prilocaine (g)
HP ₁	10	–	0.5	–	2	10	0.16	0.16
HP ₂	9	0.1	0.5	–	2	10	0.16	0.16
HP ₃	7	0.3	0.5	–	2	10	0.16	0.16
HP ₄	5	0.5	0.5	–	2	10	0.16	0.16
HP ₅	10	–	–	0.5	2	10	0.16	0.16

Table 2: Compositions of different formulations of the films prepared using EC

Formulation	EC (g)	Triacetin (g)	PG (g)	Dichloromethane (mL)	Methanol (mL)	Lidocaine (g)	Prilocaine (g)
E ₁	1.5	0.5	–	5	20	0.16	0.16
E ₂	1.5	0.5	2	5	18	0.16	0.16
E ₃	1.5	0.5	4	5	16	0.16	0.16

flow rate of 0.8 mL/min. The injection volume was 50 μ L and the UV detector was set to 220 nm.

In vitro release study

Release of lidocaine and prilocaine from HPMC and EC films in PBS (pH 7.4) as the receiver medium was evaluated by Jacketed Franz cells using dialysis membrane as a diffusion barrier at 37°C. The concentration of released drugs was assayed using HPLC. Also, the process was performed for HP₁₁ film without lidocaine and HP₁₁ film without prilocaine. Dissolution efficiency (DE) was determined as follows:

$$DE = \frac{\int_{t=0}^{t=T} y \times dt}{y_{100} \times t} \times 100 \quad (1)$$

where y is the percentage of dissolved product and DE is the area under the dissolution curve between time points $t = 0$ and $t = T$ expressed as a percentage of the curve at maximum dissolution, y_{100} , over the same time period (T). Moreover, to study the release kinetics drugs from films, the Korsmeyer–Peppas semiempirical was applied and the release data were fitted as follows^[15,16]:

$$M_t/M_\infty = K_{kp} t^n \quad (2)$$

where M_t/M_∞ is the fractional drug released at time t , K_{kp} is a constant incorporating characteristics of the drug and the

macromolecular network system, and n is diffusional release exponent which is indicative of the transport mechanism.^[16,17]

Statistical Analysis

All data were expressed as means with regard to \pm standard deviation. The statistical analysis was performed using paired t -test, analysis of variance (ANOVA), and Tukey's test to assess the significance of the differences among the various formulations.

Results and Discussion

All of films showed excellent properties in terms of film formation, ease of separation, appearance uniformity, and lack of bubbles. HP [Figure 1] and E₁ [Figure 2A] films showed transparency, whereas E₂ and E₃ films were turbid [Figure 2B and 2C].

Physical properties evaluation

Physical properties of the films are shown in Table 3. According to the results, all of the formulations (except formulation E₁) could absorb the moisture. The values for all formulations were between 31×10^{-4} and 53×10^{-4} g/cm². Unlike HPMC, the EC is a hydrophobic polymer and does not have affinity with water absorb.^[18,19] Sanpa *et al.*^[20] reported that the moisture absorption of film containing HPMC was more than the film containing EC. ANOVA statistical test is used to compare water absorption capacity of the EC films. These films presented significantly




Figure 1: Appearance of an HPMC film: (A) HP₂, (B) HP₄, and (C) HP₅




Figure 2: Appearance of the EC films: (A) E₁, (B) E₂, and (C) E₃

different capacity ($P < 0.05$). Formulation E_1 was not able to absorb moisture, but the presence of PG as a hydrophilic plasticizer^[21] in other EC films gives them hydrophilic property. In the water environment, PG dissolves and creates water-filled channels that accelerate the penetration of water into the polymer. Moisture absorption values of the HPMC films were compared with Tukey's test. No statistically difference ($P > 0.05$) was found between the triacetin-containing films (HP_1 – HP_4), but HP_5 film containing DBP (a hydrophobic plasticizer) significantly absorbed less moisture than the others ($P < 0.05$). A highly water-soluble compound such as triacetin in an HPMC matrix generates an additional osmotic gradient, thereby resulting in a faster rate of polymer swelling.^[18]

As shown in Table 3, HP_1 , HP_2 , HP_3 , and HP_4 formulations had similar tensile strength. It was found that the tensile strength of HP_5 which had a hydrophobic plasticizer (DBP) was more than other formulations. During gel preparation the hydrophilic plasticizer (triacetin) in HP_1 , HP_2 , HP_3 , and HP_4 competes with HPMC molecules to bind to active site which joins polymer molecules to each other. Reducing the number of polymer–polymer contacts leads to a decrease in the rigidity of the three-dimensional structure formed on drying and a decrease in mechanical strength of the films.^[22] The results indicated that adding PEG4000 to HP_2 , HP_3 , and HP_4 formulations had no effect on their tensile strength.

E_1 formulation showed relatively good tensile strength but its texture is brittle. The mechanical properties play an important role in the patch final performances as they should possess an adequate flexibility to avoid breaking.^[2] The addition of PG in E_2 and E_3 formulations caused to produce more flexible films. In the presence of a solvent, the mobility of the polymer chains is enhanced, resulting in a gradual transformation of a glassy matrix to a rubbery state.^[18] E_2 film had high tensile strength, but E_3 film showed lower tensile strength. The later film has a high ratio of PG because of liquid nature.

Drug content analysis

According to the results of Table 4, distribution of both drugs in various parts of the films was uniform.

Table 3: Physical properties of the films (mean \pm standard deviation, $n = 3$)

Formulation	Moisture absorption (g/cm ²)	Tensile strength (Mpa)
HP_1	$10^{-4} \pm 0.002 \times 53$	0.054
HP_2	$10^{-4} \pm 0.0016 \times 42$	0.056
HP_3	$10^{-4} \pm 0.0018 \times 42$	0.055
HP_4	$10^{-4} \pm 0.0014 \times 42$	0.054
HP_5	$10^{-4} \pm 0.00 \times 31$	1*
E_1	$0.00 \pm 0.00 \times \text{**}$	1.103
E_2	$10^{-4} \pm 0.00 \times 31$	2.059
E_3	$10^{-4} \pm 0.0017 \times 53$	0.676

*Significant difference with other HPMC films

** Significant difference with other EC films

In vitro drug release

Table 5 shows the DE values for the drugs released from the films and their main parameters (K_{kp} and n) for Korsmeyer–Peppas equation. The DE values of the HPMC films were compared with Tukey's test. The results indicated that substitution of a part of HPMC by PEG 4000 in the structure of the films had no effect on the release rate of drugs from HP_1 – HP_4 films [Figure 3]. These two polymers showed the same behavior with regard to moisture absorption, mechanical strength, and drug release. Concerning the results of Tukey's test, DE values for the film containing DBP were less than those for the films containing triacetin ($P < 0.05$). Hydrophobic nature of DBP increased the diffusion barrier property of HPMC films and reduced moisture absorption, dissolution rate, and drug release.

The *in vitro* release data were fitted into Korsmeyer–Peppas equation to determine the mechanism of drug release from the films. Peppas found that equation 2 can be used to express drug release from swellable polymers system (e.g., systems based on HPMC, poly (vinyl alcohol), etc.) as long as these systems swell gently in contact with the penetrant. In the Korsmeyer–Peppas model, the exponent n characterizes the transport mechanism of drugs as described in Table 6. For Fickian release from a thin film, n is equal to 0.50. The second limiting case, Case- II transport, is defined by n equal to 1.00. For these two limiting cases, the constant K_{kp} has physical significance, that is, $K_{kp} = 4(D/\pi l^2)^{1/2}$ for Fickian diffusion, and $K_{kp} = 2k_0/C_0 l$ for Case-II transport. Here, D is the drug diffusion coefficient, l is the initial film thickness, k_0 is defined as the Case-II relaxation constant, and C_0 is a constant drug concentration on the surfaces of the thin film during release process. Many release processes from swellable polymers fall between these two limiting cases. Anomalous release behavior is intermediate between diffusion-controlled and relaxation-controlled (and/or erosion-controlled) release and defined by values of n between 0.50 and 1.^[17] For lidocaine and prilocaine release from HP_1 – HP_4 films, n values were equal or near 1 so the mechanism of drug release follows Case-II transport. The relaxation and swelling characteristics of HPMC and PEG 4000 matrices influence drug release kinetics so as for a time-independent pattern to be created. HP_5 films show exponential value (n) between 0.5 and 1, indicating a coupling of diffusion and relaxation mechanisms, so-called anomalous diffusion.^[17]

Table 4: Content uniformity of the films (mean \pm standard deviation, $n = 3$)

Formulation	Prilocaine (%)	Lidocaine (%)
HP_1	100.73 ± 1.88	103.69 ± 1.24
HP_2	98.31 ± 0.79	102.601 ± 1.96
HP_3	103.73 ± 2.40	104.08 ± 1.19
HP_4	103.24 ± 1.17	104.02 ± 1.75
HP_5	107.13 ± 2.66	103.44 ± 1.63
E_1	102.61 ± 1.91	104.14 ± 1.63
E_2	102.87 ± 0.069	100.70 ± 2.73
E_3	100.62 ± 1.24	99.80 ± 1.44

Table 5: DE_{3h} and kinetic parameters of drug release from the formulations (mean ± standard deviation)

Formulation no.	Prilocaine				Lidocaine			
	DE _{3h} %	R ²	K _{kp}	n	DE _{3h} %	R ²	K _{kp}	n
HP ₁	43.50 ± 2.60	0.99	2.23	0.80	28.16 ± 2.81	0.98	2.40	0.87
HP ₁ *	40.16 ± 2.26	0.99	2.42	0.88	—	—	—	—
HP ₁ **	—	—	—	—	29.23 ± 1.22	0.99	2.35	0.85
HP ₂	34.20 ± 1.53	0.97	2.84	1.04	23.99 ± 0.086	0.98	2.75	1.01
HP ₃	35.33 ± 2.85	0.96	2.57	0.94	24.10 ± 4.12	0.97	2.53	0.93
HP ₄	30.59 ± 1.069	0.99	2.46	0.90	25.36 ± 4.26	0.97	2.88	1.05
HP ₅	16.21 ± 3.04	0.98	2.14	0.76	10.69 ± 1.61	0.99	1.87	0.62
E ₁	19.38 ± 3.30	0.98	1.80	0.58	13.60 ± 2.68	0.98	1.66	0.51
E ₂	17.65 ± 0.99	0.92	2.91	1.07	12.28 ± 0.74	0.95	2.27	0.82
E ₃	22.65 ± 1.49	0.99	3.00	1.09	16.93 ± 0.48	0.97	2.74	1.01

*Lidocaine free HP₁ film

**Prilocaine free HP₁ film




Figure 3: Release profiles of (A) prilocaine and (B) lidocaine from HPMC films

The *n* values for E₁ (0.511 and 0.588 for lidocaine and prilocaine, respectively) appear to indicate that diffusion is the dominant mechanism of drug release from this formulation. In contrast, the *in vitro* release profiles of E₂ and E₃ with comparatively higher exponential (*n*) values (close to 1) can be best expressed by zero-order kinetics. These formulations contained PG which dissolves in the water environment, resulting in matrix erosion and creates a time-independent

Table 6: Drug release mechanisms and diffusion exponent for polymeric controlled delivery systems of thin film^[23,24]

Diffusional release exponent (<i>n</i>)	Overall solute diffusion mechanism
0.5	Fickian diffusion
0.5 < <i>n</i> < 1	Anomalous (non-Fickian) diffusion
1	Case-II transport (zero-order or time-independent release)
<i>n</i> > 1	Super Case-II transport




Figure 4: Release profiles of (A) prilocaine and (B) lidocaine from EC films

drug release. On the contrary, in the presence of PG as a pore agent, drug diffusion is accelerated and for poorly water-soluble drugs, dissolution will be the rate-determining step of drug release. If a saturated drug solution is maintained in matrix for a long time, the system poses a zero-order release.

As shown in Figure 4, drug release from EC films (with and without PG) is accompanied by some delay. These lag times are related to required time to dissolve water-soluble materials of matrix (triacetin and PG) in the water environment to produce channels that accelerate the diffusion of the drugs out of the films. In comparison with other formulations, HP₁ and HP₅ showed the highest and the lowest rate of drug release, respectively. To study the effect of eutectic mixture of lidocaine and prilocaine on pattern of release, two formulations similar to HP₁ containing just prilocaine or lidocaine were prepared and their drug release were evaluated [Table 5 and Figure 5]. Paired *t*-test was used to compare drug release profiles of HP₁ formulation films with lidocaine free or prilocaine free corresponding films. Both paired groups showed the same release behavior ($P > 0.05$). No significant differences were found between DE and kinetics mechanism of prilocaine and lidocaine released from HP₁ and the same formulations containing only one drug ($P > 0.05$).




Figure 5: Release profiles of (A) prilocaine from HP₁ and lidocaine free HP₁* and (B) lidocaine from HP₁ and prilocaine

Conclusion

The presence of PG on the EC films caused an enhancement of the moisture absorption and the rate of drug release and shifted the mechanism of release from Fickian diffusion to Case-II transport. However, existence of PEG 4000 as a hydrophilic polymer in the structure of the HPMC films had no effect on these parameters. DBP could increase tensile strength of HPMC films, although it reduced the moisture absorption and their drug release rate. According to the results of the study, eutectic mixture could not increase the release rate of drugs. Thus, further studies are needed in order to investigate the effect of this mixture on the absorption rate of two anesthetics.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

- Delgado-Charro MB, Guy RH. Effective use of transdermal drug delivery in children. *Adv Drug Deliv Rev* 2014;73:63-82.
- Mazzitelli S, Pagano C, Giusepponi D, Nastruzzi C, Perioli L. Hydrogel blends with adjustable properties as patches for transdermal delivery. *Int J Pharm* 2013;454:47-57.
- Padula C, Nicoli S, Colombo P, Santi P. Single-layer transdermal film containing lidocaine: Modulation of drug release. *Eur J Pharm Biopharm* 2007;66:422-8.
- Saluja S, Kasha PC, Paturi J, Anderson C, Morris R, Banga AK. A novel electronic skin patch for delivery and pharmacokinetic evaluation of donepezil following transdermal iontophoresis. *Int J Pharm* 2013;453:395-9.
- Zaid Alkilani A, Hamed R, Al-Marabeh S, Kamal A, Abu-Huwaij R, Hamad I. Nanoemulsion-based film formulation for transdermal delivery of carvedilol. *J Drug Delivery Sci Technol* 2018;46:122-8.
- Telange DR, Nirgulkar SB, Umekar MJ, Patil AT, Pethe AM, Bali NR. Enhanced transdermal permeation and anti-inflammatory potential of phospholipids complex-loaded matrix film of umbelliferone: Formulation development, physico-chemical and functional characterization. *Eur J Pharm Sci* 2019;131:23-38.
- Shin SC, Cho CW, Yang KH. Development of lidocaine gels for enhanced local anesthetic action. *Int J Pharm* 2004;287:73-8.
- Rahbar N, Ramezani Z, Babapour A. Electro-oxidation mechanism and direct square-wave voltammetric determination of lidocaine with a carbon-paste electrode. *Jundishapur J Nat Pharm Prod* 2015;10:e19382.
- Moffat AC, Osselton MD, Widdop B, Watts J. Clarke's analysis of drugs and poisons. London, UK: Pharmaceutical Press; 2011.
- Sweetman SC. Martindale: The complete drug reference. London, UK: Pharmaceutical Press; 2009. p. 29-31.
- Wiseman LR, Faulds D. Oral pilocarpine: A review of its pharmacological properties and clinical potential in xerostomia. *Drugs* 1995;49:143-55.
- Friedman PM, Mafong EA, Friedman ES, Geronemus RG. Topical anesthetics update: Emla and beyond. *Dermatol Surg* 2001;27:1019-26.
- Bavarsad N, Kouchak M, Varmaziari M, Sadeghi-Nejad B. Preparation, characterization and evaluation of antifungal efficacy of chitosan/soy phosphatidylcholine topical films containing griseofulvin. *Jundishapur J Nat Pharm Prod* 2015;10:e27562.

14. Kouchak M, Ameri A, Naseri B, Kargar Boldaji S. Chitosan and polyvinyl alcohol composite films containing nitrofurazone: Preparation and evaluation. *Iran J Basic Med Sci* 2014;17:14-20.
15. Abouhusein D, El-Bary AA, Shalaby S, El Nabarawi M. Chitosan mucoadhesive buccal films: Effect of different casting solvents on their physicochemical properties. *Int J Pharm Pharm Sci* 2016;8:206-13.
16. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. *Int J Pharm* 1983;15:25-35.
17. Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. *J Controlled Release* 1987;5:37-42.
18. Enayatifard R, Saeedi M, Akbari J, Tabatabaee YH. Effect of hydroxypropyl methylcellulose and ethyl cellulose content on release profile and kinetics of diltiazem HCl from matrices. *Trop J Pharm Res* 2009;8:425-432.
19. Heng PW, Chan LW, Ong KT. Influence of storage conditions and type of plasticizers on ethylcellulose and acrylate films formed from aqueous dispersions. *J Pharm Pharm Sci* 2003;6:334-44.
20. Sanap GS, Dama GY, Hande AS, Karpe SP, Nalawade SV, Kakade RS, *et al.* Preparation of transdermal monolithic systems of indapamide by solvent casting method and the use of vegetable oils as permeation enhancer G. *IJGP* 2008;2:129-133.
21. Osorio FA, Molina P, Matiacevich S, Enrione J, Skurtys O. Characteristics of hydroxy propyl methyl cellulose (HPMC) based edible film developed for blueberry coatings. *Procedia Food Sci* 2011;1:287-93.
22. Honary S, Golkar M. Effect of polymer grade and plasticizer molecular weights on viscoelastic behavior of coating solutions. *Iran J Pharm Res* 2010;2:125-7.
23. Kaur D, Raina A, Singh N. Formulation and evaluation of carbopol 940 based glibenclamide transdermal gel. *Int J Pharm Pharm Sci* 2014;6:434-40.
24. Giri TK, Kumar K, Alexander A, Ajazuddin, Badwaik H, Tripathi DK. A novel and alternative approach to controlled release drug delivery system based on solid dispersion technique. *Bull Fac Pharm (Cairo Univ)* 2012;50:147-59.